Enveda Biosciences Hires Chief Medical Officer to Advance Its Rich Pipeline of Therapeutic Programs into the Clinic
01 Agosto 2024 - 7:00AM
Business Wire
Enveda Biosciences (“Enveda”), a biotechnology company using AI
to translate nature into new medicines, announced today the
appointment of José Trevejo M.D. Ph.D., as Chief Medical Officer
and Head of Clinical Pipeline Strategy. In this role, Dr. Trevejo
will lead the clinical organization and oversee the advancement of
Enveda’s robust pipeline that spans multiple therapeutic areas.
Dr. Trevejo joins Enveda following a string of recent successes,
most recently at Tarsus Pharmaceuticals, where he helped lead the
FDA approval and launch of a novel category-creating ophthalmic
treatment along with multiple positive Phase 2 readouts. He brings
more than fifteen years of leadership and drug development
expertise to Enveda, spanning the entire clinical development
process from proof-of-concept through approval and early
commercialization. Dr. Trevejo has worked across numerous
therapeutic areas, including GI, dermatology, ophthalmology,
infectious disease, cardiac and metabolic disease as well as
immunology.
“We are incredibly excited to welcome Dr. José Trevejo to our
leadership team,” said Viswa Colluru, Ph.D., CEO and Founder of
Enveda. “His entrepreneurial spirit is further complemented by the
operational excellence that he learned from his time at Vertex,
Genentech and other successful biopharma companies. His deep
background in shepherding novel therapies successfully through
clinical trials will be essential to Enveda’s success as we prepare
our first two drug candidates for transition into human clinical
trials, with many more close behind.”
“It is a huge honor to be joining Enveda at this transformative
phase of the company,” says Dr. Trevejo. “Enveda’s approach to
identifying new molecules from nature using AI and then adapting
them into novel medicines is compelling. However, Enveda’s platform
offers more than just a technological breakthrough in identifying
novel chemical entities, as the drug candidates in Enveda’s
pipeline have the potential to address high impact diseases for
patients across a range of therapeutic areas. I believe Enveda’s
approach will potentially offer new hope to these patients, and I
am excited by the opportunity to contribute to such an innovative
company and culture that represents the cutting edge of drug
discovery and development.”
José Trevejo M.D., Ph.D. is a physician-scientist and
biotechnology executive who has led organizations in the
development of high impact medicines spanning multiple therapeutic
areas. Prior to Enveda he was the CMO of Tarsus Pharma where he
helped lead the FDA approval and successful launch of a novel
category-creating ophthalmology drug. Dr.Trevejo also served as CDO
for Rocket Pharmaceuticals and CEO of the non-viral gene therapy
company SmartPharm, which was acquired in 2020. Prior to
SmartPharm, Jose held increasing roles of responsibility at
Ironwood, Genentech and Vertex Pharmaceuticals. Jose Trevejo
received his M.D. and Ph.D. at the Cornell-Rockefeller-Sloan
Kettering Tri-Institutional M.D./Ph.D. Program and completed his
residency and specialty training at Harvard Medical School
affiliates BWH and BIDMC.
About Enveda Biosciences
Founded in 2019, Enveda is a biotechnology company aiming to
understand and utilize the chemistry that forms the foundation of
life. Using their AI-powered tools to identify and characterize the
wide range of molecules that are produced by living organisms – the
vast majority of which have never been explored by science – Enveda
is creating a new database of chemical biodiversity: the library of
life. By growing, organizing, translating, and searching this
unique library, Enveda learns from life’s evolved solutions to
address today’s pressing clinical needs. For more information on
Enveda, visit enveda.com.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20240801312880/en/
PR@Envedabio.com